Bioanalytical Testing CROs in United States

Global leader in providing preclinical and clinical laboratory services. Charles River offers early-stage discovery, safety assessment, and clinical support services to pharmaceutical and biotech companies worldwide.

Formerly Covance, Labcorp Drug Development provides comprehensive drug development services from early discovery through post-approval. One of the world's largest CROs with extensive nonclinical and clinical capabilities.

A leading global contract research organization acquired by Thermo Fisher Scientific. PPD provides comprehensive clinical development services including laboratory, data management, and regulatory services.

Preclinical ADME and pharmacokinetics CRO in Pennsylvania providing in vitro and in vivo absorption, distribution, metabolism, and excretion studies as part of Pharmaron's global network.

Exton, Pennsylvania-based preclinical CRO providing in vivo PK/PD studies, ADME services, and GLP bioanalytical testing for small-molecule and biologic drug candidates.

San Diego-based preclinical CRO providing in vitro ADME screening, permeability assays, and metabolic stability studies for drug discovery programmes.

Specialty bioanalytical and analytical CRO providing method development, validation, and sample analysis services for pharmaceutical and biotech companies pursuing FDA submissions.

Specialist bioanalytical CRO combining LC-MS/MS, mass spectrometry imaging, and spatial biology platforms to support regulated discovery and clinical sample analysis.

GLP-compliant bioanalytical CRO with 25+ years of LC-MS/MS and GC-MS/MS expertise supporting preclinical-to-clinical drug development from purpose-built facilities.

Full-service CRO integrating translational sciences, clinical pharmacology, bioanalysis, and regulatory strategy from preclinical through Phase IV development.

Specialty preclinical CRO offering bioanalytical chemistry, in vitro ADME screening, physicochemical profiling, and metabolite identification for drug discovery programs.

Clinical pharmacology and bioanalytical CRO providing Phase I studies, bioequivalence, and PK/PD studies from a purpose-built 150-bed clinical pharmacology unit in Dilworth, Minnesota.

Independent nonprofit applied science and technology organization providing preclinical research, inhalation toxicology, bioanalytical services, and pharmaceutical development support.

World's largest nonprofit R&D organization offering GLP-compliant preclinical safety, toxicology, inhalation studies, and bioanalytical services including BSL-3 biocontainment capabilities.

Leading large molecule bioanalytical CRO specializing in ligand-binding assays, immunogenicity testing, flow cytometry, and biomarker analysis for biologics drug development.

Specialized early clinical research CRO providing Phase I clinical pharmacology, bioanalytical, and ADME services from dedicated clinical units.

Celerion's clinical pharmacology facility in Lincoln, Nebraska, providing early-phase clinical trials, BA/BE studies, and cardiac safety testing with a 200+ bed Phase I unit.

AI-enabled precision oncology CRO using patient-derived xenograft models and ex vivo pharmacology to generate predictive therapeutic response data for drug developers.

Preclinical oncology CRO using patient-derived tumor models and TumorGraft technology for in vivo efficacy studies, providing translational research services for oncology drug development.

New York-based Phase I CRO operating an 80-bed clinical pharmacology unit for first-in-human, CNS, cardiac safety, and abuse liability studies.

Full-service clinical CRO providing Phase I-IV development support with emphasis on bioanalytical services, clinical pharmacology, and PK/PD modeling from their Salt Lake City operations.

Labcorp's early development and Phase 1 clinical unit operating dedicated clinical pharmacology facilities. Provides first-in-human, bioavailability/bioequivalence, and thorough QT studies.

Leading analytical and testing laboratory providing stability testing, extractables and leachables, raw material testing, and method development for pharmaceutical and food industries.

Specialty genomics laboratory providing biomarker services, companion diagnostics, and genomic profiling for clinical trials. Part of LabCorp Drug Development.

San Diego-based CRO specialising in dermatology clinical trials with proprietary non-invasive skin sampling technology for melanoma and inflammatory skin disease studies.

Specialty reference laboratory providing clinical trial testing services including infectious disease biomarker analysis, transplant diagnostics, and immunogenicity testing for clinical studies.

Specialist preclinical ophthalmology CRO with AAALAC-accredited labs in Oklahoma City and Ann Arbor, providing pharmacology, PK/tox, bioanalysis, and formulation services for ocular drug development.

Texas-based Phase I clinical research unit specialising in early-phase, first-in-human, and healthy volunteer studies with integrated bioanalytical capabilities.

Clinical trial arm of Frontage Laboratories providing Phase I-III services with integrated bioanalytical capabilities, bridging bioanalytical strength with full clinical execution.

CRO providing integrated drug discovery and development services including ADME/PK, bioanalytical, CMC, and clinical services with operations in the US and China.

Phase I clinical research unit in New Jersey providing first-in-human, food effect, bioequivalence, and early-phase pharmacokinetic studies for pharmaceutical sponsors.

ICON's dedicated bioanalytical division providing GLP-compliant small and large molecule bioanalysis, immunogenicity testing, and biomarker analysis from state-of-the-art laboratories.

Specialised bioanalytical laboratory in New York providing large-molecule bioanalysis, immunogenicity testing, and ligand-binding assay development for biologics programmes.

ICON's dedicated early development division operating clinical pharmacology units in the US and Europe, conducting first-in-human, PK/PD, food effect, and drug interaction studies.

Contract research organization providing drug discovery and development services including preclinical safety assessment, bioanalytical services, and research animal models.

Leading bioanalytical CRO with 45+ years of experience supporting 315+ approved drugs, offering LC-MS, ELISA, flow cytometry, and immunogenicity assays.

Pennsylvania-based bioanalytical CRO providing GLP-compliant LC-MS/MS and ligand-binding assay services for PK, immunogenicity, and biomarker analysis.

Large preclinical CRO in Michigan acquired by Charles River Laboratories, providing GLP toxicology, safety pharmacology, and ADME studies in purpose-built facilities spanning over 800,000 sq ft.

Specialist topical and transdermal formulation development CRO and CDMO offering dermal PK, in vitro permeation, bioequivalence, and formulation development services.

Scientifically-driven, global, full-service clinical CRO providing Phase I-IV clinical development services. Medpace is known for its therapeutic expertise and operational efficiency.

Founder-led bioanalytical CRO providing GLP-compliant LC-MS, ELISA, and qPCR services for PK, immunogenicity, and biomarker assays for pharma and biotech.

Drug discovery services company providing in vitro pharmacology screening, ADME profiling, and custom assay development for pharmaceutical and biotech companies.

US arm of Australian CRO Nucleus Network, operating early phase clinical trials from their Minneapolis facility. Provides Phase 1 studies with access to diverse patient populations.

US-based contract analytical laboratory providing GMP/GLP method development, validation, stability testing, and extractables/leachables studies for pharmaceutical and biotech sponsors.

Bioanalytical CRO providing GLP-compliant LC-MS/MS and ligand binding assay services for pharmacokinetic, bioequivalence, and immunogenicity sample analysis to support clinical trials.

California-based bioanalytical CRO providing LC-MS/MS method development, validation, and sample analysis for PK/PD studies supporting IND and NDA submissions.

Bioanalytical and testing laboratory in the San Francisco Bay Area providing biocompatibility testing, extractables and leachables, sterility, and analytical chemistry services for pharma and medical devices.

Specialty CRO focused on oncology and rare disease with 2,000+ professionals, known for biomarker-driven trial design, companion diagnostics, and translational research services.

Specialty CRO focused on cardiometabolic clinical trials. Operates Phase 1–2 studies for obesity, diabetes, NASH/MASH, and cardiovascular endpoints with proprietary biomarker platforms.

Global CRO providing bioanalytical, clinical pharmacology, and Phase I-IV clinical trial services. QPS operates CLIA-certified bioanalytical laboratories supporting regulated studies.

Specialty CRO providing GLP toxicology testing, biocompatibility evaluation, and analytical chemistry services for medical devices, combination products, and pharmaceutical excipients.

Translational pharmaceutics CRO/CDMO uniquely combining formulation development and clinical pharmacology under one roof, accelerating drug development timelines by running formulation and clinical testing simultaneously.

Oklahoma-based early-phase clinical research site specialising in Phase I healthy volunteer studies, PK/PD trials, and bioequivalence studies.

Specialist bioanalytical, biomarker, and analytical sciences CRO with 500+ experts providing FDA/EMA-inspection-ready regulated bioanalysis across the US, UK, and Australia.

US subsidiary of Shin Nippon Biomedical Laboratories specializing in GLP preclinical safety assessment including general toxicology, reproductive toxicology, and inhalation studies with NHP and rodent capabilities.

Nonprofit research organization providing drug discovery, preclinical development, and analytical services with deep expertise in oncology and infectious disease including BSL-3 capabilities.

Oncology-focused CRO founded on the Mayo Clinic campus offering preclinical-to-clinical oncology development with PDX models, flow cytometry, and Phase I/II trial management.

Clinical-stage diagnostics and genomic testing company providing companion diagnostic development and biomarker-driven clinical trial services.

Mid-size global CRO providing Phase I-IV clinical development services with expertise in CNS, cardiovascular, and metabolic disease therapeutic areas.

Mid-size full-service global CRO offering integrated bioanalytical lab services alongside Phase I-IV clinical trial management with a focus on CNS, cardiovascular, and rare disease.

New Jersey-based bioanalytical and ADME/DMPK CRO founded in 1987, providing clinical and nonclinical metabolism and pharmacokinetics services to pharma, biotech, and agrochemical industries.

Kansas City-based in vitro ADME and drug metabolism CRO providing hepatocyte-based assays, enzyme induction/inhibition studies, and metabolite identification services.